Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer

Seven tyrosine kinase inhibitor compounds with anti-angiogenic properties remain key drugs to treat advanced renal cell carcinoma. There is a strong rationale to develop therapeutic drug monitoring for these drugs. General considerations of such monitoring of the several groups of anticancer drugs a...

Full description

Bibliographic Details
Main Authors:	Florent Puisset, Mourad Mseddi, Loïc Mourey, Damien Pouessel, Benoit Blanchet, Etienne Chatelut, Christine Chevreau
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Cancers
Subjects:	therapeutic drug monitoring tyrosine kinase inhibitors renal cancer
Online Access:	https://www.mdpi.com/2072-6694/15/1/313

Similar Items

Review : Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
by: Ronald M Bukowski
Published: (2012-02-01)

Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
by: Kalpana K. Bhanumathy, et al.
Published: (2021-01-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Novel Tyrosine Kinase Targets in Urothelial Carcinoma
by: Javier Torres-Jiménez, et al.
Published: (2021-01-01)

Tyrosine Kinase Receptors in Oncology
by: Jorge Esteban-Villarrubia, et al.
Published: (2020-11-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
by: Qinlian Jiao, et al.
Published: (2018-02-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
by: Kun Wang, et al.
Published: (2023-07-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
by: Chen-Yu Hu, et al.
Published: (2019-12-01)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
by: Paula Aldaz, et al.
Published: (2021-11-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
by: D. Samuel Metibemu, et al.
Published: (2019-12-01)

Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma
by: Ming Zeng, et al.
Published: (2024-03-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
by: Manali Tilak, et al.
Published: (2021-02-01)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
by: Jakob Michaelis, et al.
Published: (2022-08-01)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
by: Krisztina Futosi, et al.
Published: (2023-04-01)

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials
by: Muhammad Ashar Ali, et al.
Published: (2023-01-01)

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
by: Le Qiu, et al.
Published: (2014-07-01)

Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study
by: Vanesa Escudero-Ortiz, et al.
Published: (2022-06-01)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
by: Ainun Nizar Masbuchin, et al.
Published: (2022-09-01)

Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
by: Takuto Shimizu, et al.
Published: (2024-02-01)

Editorial: Tyrosine kinases and phosphatases in T- cell malignancies
by: Melania Tesio
Published: (2024-02-01)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
by: Emmy D. G. Fleuren, et al.
Published: (2023-03-01)

Protein tyrosine kinases in Schistosoma mansoni
by: Diana Bahia, et al.
Published: (2006-10-01)

Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis
by: Ying Xiong, et al.
Published: (2022-11-01)

Recent Advances in the Role of Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Breast and Ovarian Cancer
by: Li Chen, et al.
Published: (2021-11-01)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
by: Yassir Sbitti, et al.
Published: (2018-03-01)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
by: Yang Liu, et al.
Published: (2021-02-01)

Metastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
by: AlAzab RS, et al.
Published: (2019-11-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
by: Hor-Yue Tan, et al.
Published: (2018-02-01)

Connexin43 is associated with the progression of clear cell renal carcinoma and is regulated by tangeretin to sygergize with tyrosine kinase inhibitors
by: Yongchang Lai, et al.
Published: (2023-09-01)

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
by: Kinga Krawczyk, et al.
Published: (2023-09-01)

Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
by: Yu Liu, et al.
Published: (2019-06-01)

Tyrosine kinase targeting: A potential therapeutic strategy for diabetes
by: Mohammad Althubiti
Published: (2022-01-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
by: Jiangnan Liu, et al.
Published: (2024-03-01)

Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
by: Vineet Agrawal, et al.
Published: (2015-02-01)

The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy
by: Zhusheng Zhang, et al.
Published: (2022-12-01)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
by: Nick Verougstraete, et al.
Published: (2022-03-01)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)

Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma
by: Jiajun Wang, et al.
Published: (2019-01-01)